Back to Stocks

TOVX

Theriva Biologics, Inc.
7 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Theriva Biologics is transitioning from a high-burn clinical entity into a disciplined, catalyst-driven oncology platform. The company has successfully slashed its research and development expenditures by 88% year-over-year, reducing quarterly net losses to $2.04 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of operational efficiency, Theriva's financial foundation remains precarious.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every TOVX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-Q reveals a company at a critical crossroads, attempting to bridge the gap between a depleted balance sheet and a promising clinical roadmap. While the FDA's agreement on the Phase 3 design for VCN-01 is a major regulatory victory, the financial reality is a race against time. The company has successfully pivoted its focus and reduced its burn rate, but it remains fundamentally dependent on external financing or a strategic partnership to reach its 2029 goals. Investors are essentially betting on the successful execution of a narrow clinical window. The ability to secure a strategic partner or a non-dilutive funding source will be the deciding factor in whether Theriva can navigate its contingent liabilities and reach the BLA submission phase. Until then, the stock remains a high-risk, high-reward play centered on the binary success of a single oncology asset.

Selected Quarter

Core Takeaway

Theriva has successfully reduced its burn rate and gained FDA alignment for its lead asset, but it faces a critical cash crunch due to deferred milestone payments.

Investor Lens

The trade-off is between the high potential of a validated oncology platform and the immediate risk of a liquidity-driven collapse or extreme dilution.

Watch Next

Announcement of the Phase 2a dosing feasibility study commencement in Spain and any resolution of the deferred Grifols payment.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.25Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 5

R&D expenses collapsed by 88% year-over-year, significantly reducing quarterly net loss.

margin expansion
80%
neutralMay 5

Generated $2.3 million through ATM equity sales to maintain liquidity.

capital raise
50%
bullishMay 5

FDA provided general agreement on the proposed Phase 3 clinical trial design for VCN-01.

regulatory action
90%
bearishMay 5

Substantial doubt about ability to continue as a going concern due to deferred milestone liabilities.

debt restructure
70%
bullishMay 5

R&D expenses collapsed by 88% year-over-year, significantly reducing quarterly net loss.

margin expansion
80%
neutralMay 5

Generated $2.3 million through ATM equity sales to maintain liquidity.

capital raise
50%
bullishMay 5

FDA provided general agreement on the proposed Phase 3 clinical trial design for VCN-01.

regulatory action
90%
bearishMay 5

Substantial doubt about ability to continue as a going concern due to deferred milestone liabilities.

debt restructure
70%
bullishMay 5

R&D expenses collapsed by 88% year-over-year, significantly reducing quarterly net loss.

margin expansion
80%
neutralMay 5

Generated $2.3 million through ATM equity sales to maintain liquidity.

capital raise
50%
bullishMay 5

FDA provided general agreement on the proposed Phase 3 clinical trial design for VCN-01.

regulatory action
90%
bearishMay 5

Substantial doubt about ability to continue as a going concern due to deferred milestone liabilities.

debt restructure
70%
bullishMay 5

R&D expenses collapsed by 88% year-over-year, significantly reducing quarterly net loss.

margin expansion
80%
neutralMay 5

Generated $2.3 million through ATM equity sales to maintain liquidity.

capital raise
50%
bullishMay 5

FDA provided general agreement on the proposed Phase 3 clinical trial design for VCN-01.

regulatory action
90%
bearishMay 5

Substantial doubt about ability to continue as a going concern due to deferred milestone liabilities.

debt restructure
70%
bullishMay 5

R&D expenses collapsed by 88% year-over-year, significantly reducing quarterly net loss.

margin expansion
80%
neutralMay 5

Generated $2.3 million through ATM equity sales to maintain liquidity.

capital raise
50%
bullishMay 5

FDA provided general agreement on the proposed Phase 3 clinical trial design for VCN-01.

regulatory action
90%
bearishMay 5

Substantial doubt about ability to continue as a going concern due to deferred milestone liabilities.

debt restructure
70%
bullishMay 5

R&D expenses collapsed by 88% year-over-year, significantly reducing quarterly net loss.

margin expansion
80%
neutralMay 5

Generated $2.3 million through ATM equity sales to maintain liquidity.

capital raise
50%
bullishMay 5

FDA provided general agreement on the proposed Phase 3 clinical trial design for VCN-01.

regulatory action
90%
bearishMay 5

Substantial doubt about ability to continue as a going concern due to deferred milestone liabilities.

debt restructure
70%
bullishMay 5

R&D expenses collapsed by 88% year-over-year, significantly reducing quarterly net loss.

margin expansion
80%
neutralMay 5

Generated $2.3 million through ATM equity sales to maintain liquidity.

capital raise
50%
bullishMay 5

FDA provided general agreement on the proposed Phase 3 clinical trial design for VCN-01.

regulatory action
90%
bearishMay 5

Substantial doubt about ability to continue as a going concern due to deferred milestone liabilities.

debt restructure
70%

Filing History

10-QMay 5, 2026
Expand Sequence

The 10-Q reveals a company at a critical crossroads, attempting to bridge the gap between a depleted balance sheet and a promising clinical roadmap. While the FDA's agreement on the Phase 3 design for VCN-01 is a major regulatory victory, the financial reality is a race against time. The company has successfully pivoted its focus and reduced its burn rate, but it remains fundamentally dependent on external financing or a strategic partnership to reach its 2029 goals. Investors are essentially betting on the successful execution of a narrow clinical window. The ability to secure a strategic partner or a non-dilutive funding source will be the deciding factor in whether Theriva can navigate its contingent liabilities and reach the BLA submission phase. Until then, the stock remains a high-risk, high-reward play centered on the binary success of a single oncology asset.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.